The document discusses the challenges in cancer treatment, particularly genetic resistance to drugs, and highlights the work of Dr. Daniel Haber and Dr. Mehmet Toner in developing a blood test to detect circulating tumor cells (CTCs). This test, supported by the Jeffrey Epstein VI Foundation and other organizations, isolates cancer cells for genetic analysis, aiding in targeted cancer therapies. The document also addresses the issue of secondary mutations leading to drug resistance and the potential of the CTC test to preemptively treat these mutations. Jeffrey Epstein's foundation is noted for supporting this research.
documents/EFTA01085311.pdf
{}